Skip to main content
Glama

Schemastore

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Despite annotations already marking the tool read-only and non-destructive, the description adds rich behavioral context: internal cascading through multiple lookup endpoints, graceful degradation when GLEIF or OpenFIGI is unavailable, returning figi_candidates and asserting nothing on ambiguous matches, and explicitly listing unresolved identifiers rather than omitting them. This goes well beyond the annotation hints.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense and information-rich, and almost all content earns its place for a complex resolution tool. However, the opening sentence is a very long run-on with nested parentheticals and many examples, so it is more heavy than concise; shorter, more front-loaded sentences would improve scannability.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema present, the description carries the full burden of explaining return behavior, and it does so thoroughly: identifiers are source-labelled, unresolved IDs appear under unresolved, ambiguous matches return figi_candidates, and both company and drug result fields are specified. It also covers failure modes such as unavailable enrichment services and non-US issuers, leaving nothing critical unspecified.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The schema already describes both parameters, but the description materially extends them by revealing that company input accepts ISIN in addition to ticker/CIK/name, explaining the ISIN-to-LEI path, and warning that the agent must pass only the entity name, not the full noun phrase, because the FIGI lookup matches instrument names. This is high-value guidance beyond the property descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete user phrasings and states a precise action: resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. It enumerates supported entity types (company/drug) and explicitly positions itself as the tool to use first when a name needs an ID, which separates it from lookup/profile siblings.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

'Use FIRST whenever you have a name but need an ID' gives an explicit triggering condition and situates the tool relative to downstream tools. However, it does not explicitly name sibling alternatives or explain when to choose lookup/entity_profile instead, so it stops short of a full when-to-use/when-not-to-use guide.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Schemastore toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.8/5.0
Disambiguation3/5

Several tools occupy overlapping semantic space: ask_pipeworx, ask_pipeworx_beta (currently identical), and ask_pipeworx_grounded are the same router in different modes, while suggest_questions and discover_tools both serve capability discovery. The detailed descriptions help, but an agent could easily select the wrong entry point, especially among the prediction-market and router variants.

Naming Consistency4/5

All tool names use lowercase snake_case and mostly follow a verb_noun pattern (fetch_schema, resolve_entity, validate_claim), with some domain-prefixed nouns (polymarket_edges, pipeworx_trending) and a few adjective_noun outliers (recent_alerts, recent_changes). The convention is consistent and predictable, with only minor deviations.

Tool Count2/5

At 35 tools, the set is far too large for a server named Schemastore — only four tools relate to the schema catalog while the rest form a sprawling data-research, prediction-market, memory, and subscription platform. The count is heavy and the scope feels unfocused.

Completeness3/5

The broad data-research and prediction-market domain is well covered — lookup, compare, validate, research, arbitrage, subscriptions, and memory all have lifecycle support — but the server's namesake purpose (schema catalog) is thinly served by four read-only tools with no way to contribute or manage schemas. The domain mismatch makes the surface feel both over- and under-complete.

Resources